A coordinated Form 144 cluster by MPM entities at a ~$24M market cap is a strong bearish signal for HOWL. These are likely early-stage investors seeking to exit, creating overhang. Monitor for actual sales in coming days; if the selling pressure materializes, HOWL could face significant downside given the low liquidity of a $24M micro-cap. Consider short positions or avoiding HOWL until the distribution clears.
Price Chart
Executive Summary
A cluster of 8 Form 144 filings by MPM-affiliated entities (MPM Oncology Innovations Fund, MPM Asset Management, UBS Oncology Impact Fund, and multiple MPM BioVentures funds) were filed on 2026-05-28, signaling intent to sell shares of Werewolf Therapeutics (HOWL). The filings are aggregate across the MPM platform and represent a coordinated insider distribution. At a ~$24M market cap, the selling entities appear to be major early investors. This batch follows 10 insider sells totaling $346K in the past 30 days, reinforcing a pattern of liquidation by large holders.
Key Facts
- 8 Form 144 filings filed on 2026-05-28 by MPM-affiliated funds and UBS Oncology Impact Fund
- Selling entities include MPM Oncology Innovations Fund LP, MPM Asset Management Investors BV2014 LLC, MPM ASSET MANAGEMENT LLC, UBS Oncology Impact Fund LP, MPM BioVentures 2014 (B) LP, MPM BioVentures 2014 LP
- All filings specify intent to sell shares of Werewolf Therapeutics (HOWL) common stock
- Prior 30 days show 10 insider sales totaling ~$346K
- Market cap is approximately $24M — a small-cap, early-stage biotech
- No specific share amounts or dollar values are available in the document text
- This is a coordinated distribution by major early investors, not a single insider
Financial Impact
Material — multiple large holders signaling exit at a $24M market cap, representing a significant portion of the float
Risk Factors
- Form 144 indicates intent, not guaranteed sale — sales may not occur
- If MPM entities sell a large block, the stock could gap down significantly
- Low market cap ($24M) amplifies impact of any insider selling on price
- Biotech sector risk — negative clinical data could compound selling pressure
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 8 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 144 Filing (HOWL) — Batch item 1 | 0001628280-26-038889 |
| Document: 0001628280-26-038889-index.html | 0001628280-26-038891 |
| Document: 0001628280-26-038889.txt | 0001628280-26-038892 |
| 144 Filing (HOWL) — Batch item 4 | 0001628280-26-038891 |
| 144 Filing (HOWL) — Batch item 5 | 0001628280-26-038892 |
| 144 Filing (HOWL) — Batch item 6 | 0001628280-26-038893 |
| 144 Filing (HOWL) — Batch item 7 | 0001628280-26-038895 |
| 144 Filing (HOWL) — Batch item 8 | 0001628280-26-038896 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 26, 2026 today | S-4/A | $0.9806 | awaiting T+5 | — | $1.03 (−5.04%) |
Sep 22, 2026 4w ago | S-4 | $0.9894 $0.9223 | ▲ +6.78% | ▲ +6.11% | $1.03 (−4.10%) |
Sep 21, 2026 5w ago | SC 13G | $0.9800 $0.9300 | ▼ −5.10% | ▼ −4.08% | $1.03 (+5.10%) |
Aug 21, 2026 9w ago | 425 | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $1.03 (+17.85%) |
Aug 21, 2026 9w ago | 8-K | $0.8740 $0.9433 | ▲ +7.93% | ▲ +7.46% | $1.03 (+17.85%) |
Aug 21, 2026 9w ago | Press Release | $0.8740 $0.9433 | ▼ −7.93% | ▼ −7.46% | $1.03 (−17.85%) |
Jul 31, 2026 12w ago | 8-K | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $1.03 (+191.70%) |
Jul 31, 2026 12w ago | Press Release | $0.3531 $0.3971 | ▲ +12.46% | ▲ +8.95% | $1.03 (+191.70%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $1.03 (−186.19%) |
Jun 29, 2026 17w ago | 144 | $0.3599 $0.3200 | ▲ +11.09% | ▲ +11.69% | $1.03 (−186.19%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers